Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IZABRIGHT-Breast01
2024-519871-24-00Phase 3Authorised
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 28
01
Overview
Phase 3, randomised, open-label trial of izalontamab brengitecan in breast cancer and triple-negative breast cancer (TNBC) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Progression-free survival by blinded independent central review and Recommended Phase III dose. Planned start Nov 2025; status: authorised.
02
Drugs
izalontamab brengitecan
03
Conditions
breast cancertriple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2024-519871-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519871-24-00.